Literature DB >> 27372651

Geniposide Prevents Hypoxia/Reoxygenation-Induced Apoptosis in H9c2 Cells: Improvement of Mitochondrial Dysfunction and Activation of GLP-1R and the PI3K/AKT Signaling Pathway.

You-Qin Jiang1, Guang-Lei Chang, Ying Wang, Dong-Ying Zhang, Li Cao, Jian Liu.   

Abstract

BACKGROUND/AIMS: Myocardial ischemia/reperfusion injury is a major cause of morbidity and mortality associated with coronary heart disease. Many studies have demonstrated that natural products are promising chemotherapeutic drugs counteracting the loss of cardiomyocytes. Thus, the purpose of the present study was to investigate the effects of geniposide, a traditional Chinese herb extract from Gardenia jasminoides J. Ellis, on cardiomyocyte apoptosis induced by hypoxia/reoxygenation (H/R) in H9c2 cells, and their underlying mechanisms.
METHODS: Cell viability and apoptosis ratio were assessed using the cell counting kit-8 assay and Annexin V/propidium iodide (PI) staining. The concentrations of lactate dehydrogenase (LDH), intracellular total superoxide dismutase (T-SOD), and malondialdehyde (MDA) were detected by microplate reader. The production of reactive oxygen species/reactive nitrogen species (ROS/RNS), the level of mitochondrial calcium, and mitochondrial membrane potential depolarization were measured by confocal laser scanning microscopy. Mitochondrial morphology was visualized using transmission electron microscopy. The expressions of Bcl-2 mRNA and Caspase-3 mRNA were measured by reverse transcription-polymerase chain reaction (RT-PCR). The protein levels of cleaved caspase-3, Bcl-2, Bax, AKT, p-AKTserine473, cytochrome-c were detected by western bloting.
RESULTS: Geniposide pretreatment increased cell viability, decreased LDH levels in the supernatant, and inhibited cardiomyocyte apoptosis caused by H/R. Furthermore, geniposide reversed mitochondrial dysfunction by decreasing oxidative stress products (ROS/RNS and MDA), increasing anti-oxidative enzyme (T-SOD) level, improving mitochondrial morphology, attenuating mitochondrial calcium overload and blunting depolarization of mitochondrial membrane. Moreover, geniposide pretreatment increased Bcl-2 level and decreased Bax level, thus enhancing the Bcl-2/Bax ratio. Consistent with the above result, Bcl-2 mRNA expression was upregulated and caspase-3 mRNA expression was downregulated by geniposide. In addition, geniposide decreased the protein expression of cleaved caspase-3 and cytochrome-c and increased the level p-AKTserine473. The protective effects of geniposide were partially reversed by glucagon-like pepitide-1 receptor antagonist exendin-(9-39) and the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002.
CONCLUSIONS: Our results suggest that geniposide pretreatment inhibits H/R-induced myocardial apoptosis by reversing mitochondrial dysfunction, an effect in part due to activation of GLP-1R and PI3K/AKT signaling pathway.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27372651     DOI: 10.1159/000445634

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  28 in total

1.  miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A.

Authors:  Yin Ren; Ruanzhong Bao; Zhujun Guo; Jin Kai; Chen-Ge Cai; Zhu Li
Journal:  Exp Ther Med       Date:  2020-11-23       Impact factor: 2.447

2.  Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy.

Authors:  Shiyong Wu; Guanglei Chang; Lei Gao; Dan Jiang; Liyou Wang; Guoxing Li; Xuexiu Luo; Shu Qin; Xueli Guo; Dongying Zhang
Journal:  J Mol Med (Berl)       Date:  2018-06-29       Impact factor: 4.599

3.  Phosphatidylinositol 3-kinase-mediated HO-1/CO represses Fis1 levels and alleviates lipopolysaccharide-induced oxidative injury in alveolar macrophages.

Authors:  Jia Shi; Jianbo Yu; Yuan Zhang; Zhen Li; Lirong Gong; Shuan Dong; Rui Mu
Journal:  Exp Ther Med       Date:  2018-07-17       Impact factor: 2.447

4.  An Integrative Pharmacology-Based Analysis of Refined Qingkailing Injection Against Cerebral Ischemic Stroke: A Novel Combination of Baicalin, Geniposide, Cholic Acid, and Hyodeoxycholic Acid.

Authors:  Chongyang Ma; Xueqian Wang; Tian Xu; Shuang Zhang; Shuling Liu; Changming Zhai; Zisong Wang; Jie Mu; Changxiang Li; Fafeng Cheng; Qingguo Wang
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

5.  Geniposide Attenuates LPS-Induced Injury via Up-Regulation of miR-145 in H9c2 Cells.

Authors:  Qiang Su; Junjing Yao; Cunjian Sheng
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

6.  L-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway.

Authors:  Mei Xue; Xu Chen; Zhija Guo; Xiaoqian Liu; Yanping Bi; Jie Yin; Haiyan Hu; Ping Zhu; Jian Zhuang; Courtney Cates; Thomas Rousselle; Ji Li
Journal:  Toxicol Sci       Date:  2017-12-01       Impact factor: 4.849

7.  Effect of moxibustion preconditioning on autophagy-related proteins in rats with myocardial ischemia reperfusion injury.

Authors:  Hong-Ru Zhang; Hua Bai; Eunmee Yang; Ze-Hao Zhong; Wan-Ying Chen; Yan Xiao; Yi-Huang Gu; Sheng-Feng Lu
Journal:  Ann Transl Med       Date:  2019-10

Review 8.  Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease.

Authors:  Aude Angelini; Xinchun Pi; Liang Xie
Journal:  Front Physiol       Date:  2017-12-12       Impact factor: 4.566

9.  Synergistic neuroprotective effects of Geniposide and ursodeoxycholic acid in hypoxia-reoxygenation injury in SH-SY5Y cells.

Authors:  Fafeng Cheng; Chongyang Ma; Liangming Sun; Xiaoyu Zhang; Changming Zhai; Changxiang Li; Shuang Zhang; Beida Ren; Shuling Liu; Songnan Liu; Xiangjun Yin; Xueqian Wang; Qingguo Wang
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

10.  6-Gingerol Activates PI3K/Akt and Inhibits Apoptosis to Attenuate Myocardial Ischemia/Reperfusion Injury.

Authors:  Xiangwei Lv; Tongtong Xu; Qi Wu; Yao Zhou; Guidong Huang; Yongnan Xu; Guoqiang Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.